Please login to the form below

RoActemra

This page shows the latest RoActemra news and features for those working in and with pharma, biotech and healthcare.

The EMA has laid out monitoring and mitigation strategies for these side effects, including the use of Roche’s RoActemra to treat CRS.

Roche's Actemra/RoActemra receives new European approval

GCA is a chronic and potentially life-threatening autoimmune condition and Actemra/RoActemra’s approval was based on data from the phase III GiACTA study. ... As the first effective non-steroid therapy for GCA, Actemra/RoActemra has the potential to
Ocrevus off to a flying start as Roche raises 2017 forecasts

Perjeta (pertuzumab) for breast cancer continued to grow - rising 17% to 1.07bn francs - and immunotherapy Actemra/RoActemra (tocilizumab) also put in a good showing, rising 13% to 922m francs thanks
Sanofi/Regeneron bag first approval for Actemra rival sarilumab

Sarilumab is a fully human monoclonal antibody that binds specifically to both soluble and membrane-bound IL-6 receptors, and is the first direct competitor to Roche's Actemra/RoActemra (tocilizumab)
Manufacturing issues scupper Sanofi's sarilumab launch plans

Any delay to the programme is however a blow to Sanofi and Regeneron, which are playing catch-up against the only marketed IL-6 inhibitor - Roche's Actemra/RoActemra (tocilizumab) - while
Roche snags pair of FDA breakthrough designations

Meanwhile, Roche's interleukin-6 inhibitor RoActemra/Actemra (tocilizumab) picked up a BTD for giant cell arteritis, a chronic and potentially life-threatening autoimmune condition in which serious inflammation is seen

More from news
Approximately 5 fully matching, plus 21 partially matching documents found.

Achieving remission

Campaign:RoACTEMRA / ACTEMRA: beyond the boundaries of existing treatments. Timescale:2008 to 2009. ... Online monitoring tools tracked RoACTEMRA / ACTEMRA noise, identifed top influencers and tonality of digital conversations.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

The Biosimilar Challenge

Herceptin, Avastin, Rituximab and Erbitux) and autoimmune disease (e.g. Humira, Enbrel, Remicade, MabThera and RoActemra to name a few).
Infographic: RA Perceptions

Partnership. An infographic highlights the key findings from the study. Biologic agents with novel mechanisms of action (such as Roche’s RoActemra) are expected to outperform the overall EU biologics market
Brand leaders in RA will lose market share, predict rheumatologists

leaders Enbrel (etanercept) and Humira (adalimumab) will continue to lose market share to newer biologics such as RoActemra (tocilizumab), Orencia (abatacept) and Simponi (golimumab) and may experience strong competition from biosimilar

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Account Manager / Senior Account Manager - Healthcare Advertisin...: Excellent Remuneration

NEW FREELANCE OPPORTUNITIES!!! LONDON and HOME WORKING!: EXCELLENT DAY RATES AVAILABLE

Senior Account Manager- Pharma and Life Scienes: Competitive salary and benefits

Senior Account Director/ Associate Director- Pharma and Life Sci...: Competitive salary and benefits

Experienced / Senior Account Director - Publications - London: Up to £80, 000 plus great benefits

Freelance Medical Writer - Healthcare Advertising - London: Employment Type:. Type of Job:. Region:. Salary:. 250 to 330 per day

Project Manager - Medical Communications – South Wales: Excellent Remuneration Package

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Senior / Principal Medical Writer - MedComms - Home Based / Vari...: Excellent Remuneration Packages

Editorial / Copy Lead – Healthcare Advertising – Central London...: Salary TBC

Hybrid Role - Principal Medical Writer / Account Handler - Publi...: Salary TBC

Project Manager - Digital Healthcare - London: Excellent Remuneration Package

Account Director – London based Medical Communications Agency: Excellent Remuneration Package

Add my company

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality: How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA: Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad: Six behaviours separate the good brand teams from the bad...